Form 8-K - Current report:
SEC Accession No. 0001558370-24-009915
Filing Date
2024-07-19
Accepted
2024-07-19 16:15:27
Documents
15
Period of Report
2024-07-16
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ymab-20240716x8k.htm   iXBRL 8-K 40413
2 EX-10.1 ymab-20240716xex10d1.htm EX-10.1 60714
3 EX-10.2 ymab-20240716xex10d2.htm EX-10.2 61169
  Complete submission text file 0001558370-24-009915.txt   302745

Data Files

Seq Description Document Type Size
4 EX-101.SCH ymab-20240716.xsd EX-101.SCH 3399
5 EX-101.LAB ymab-20240716_lab.xml EX-101.LAB 15926
6 EX-101.PRE ymab-20240716_pre.xml EX-101.PRE 10318
17 EXTRACTED XBRL INSTANCE DOCUMENT ymab-20240716x8k_htm.xml XML 4845
Mailing Address 230 PARK AVENUE SUITE 3350 NEW YORK NY 10169
Business Address 230 PARK AVENUE SUITE 3350 NEW YORK NY 10169 212-847-9841
Y-mAbs Therapeutics, Inc. (Filer) CIK: 0001722964 (see all company filings)

EIN.: 474619612 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38650 | Film No.: 241127952
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)